Patents by Inventor Mark X. Sliwkowski

Mark X. Sliwkowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230201210
    Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: February 17, 2023
    Publication date: June 29, 2023
    Applicant: GENENTECH, INC.
    Inventors: Mark X. Sliwkowski, Scott Holden, Stuart Lutzker, Jay Tibbitts, Nelson L. Jumbe
  • Publication number: 20230041134
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: April 14, 2022
    Publication date: February 9, 2023
    Applicant: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Publication number: 20200255539
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: December 19, 2019
    Publication date: August 13, 2020
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Patent number: 10639373
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: May 5, 2020
    Assignee: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • Patent number: 10632196
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: April 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • Publication number: 20200085840
    Abstract: The invention provides immunoconjugates comprising anti-HER2 antibodies and methods of using the same.
    Type: Application
    Filed: April 23, 2019
    Publication date: March 19, 2020
    Applicant: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Patent number: 10556966
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: February 11, 2020
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Publication number: 20190374547
    Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: August 21, 2019
    Publication date: December 12, 2019
    Applicant: GENENTECH, INC.
    Inventors: Mark X. Sliwkowski, Scott Holden, Stuart Lutzker, Jay Tibbitts, Nelson L. Jumbe
  • Publication number: 20190177429
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: October 25, 2018
    Publication date: June 13, 2019
    Applicant: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Patent number: 10314846
    Abstract: The invention provides immunoconjugates comprising anti-HER2 antibodies and methods of using the same.
    Type: Grant
    Filed: February 21, 2017
    Date of Patent: June 11, 2019
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Patent number: 10179820
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: October 18, 2016
    Date of Patent: January 15, 2019
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Publication number: 20180326062
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Application
    Filed: July 16, 2018
    Publication date: November 15, 2018
    Applicant: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • Patent number: 10058613
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: August 28, 2018
    Assignee: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • Publication number: 20180185486
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Application
    Filed: February 20, 2018
    Publication date: July 5, 2018
    Applicant: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • Patent number: 9963517
    Abstract: Compositions and methods useful for detecting and treating cancers which express the HER4 JM-a isoform are disclosed.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: May 8, 2018
    Assignees: Genentech, Inc., University of Turku
    Inventors: Mark X. Sliwkowski, Klaus Elenius, Maija Hollmen
  • Publication number: 20170274092
    Abstract: The invention provides immunoconjugates comprising anti-HER2 antibodies and methods of using the same.
    Type: Application
    Filed: February 21, 2017
    Publication date: September 28, 2017
    Applicant: GENENTECH, INC.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Publication number: 20170174782
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Application
    Filed: October 18, 2016
    Publication date: June 22, 2017
    Applicant: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski
  • Publication number: 20170136026
    Abstract: Combinations of the antibody-drug conjugate trastuzumab-MCC-DM1 and chemotherapeutic agents, including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting tumor cell growth, and for treating disorders such as cancer mediated by HER2 and KDR (VEGFR receptor 1). Methods of using such combinations for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: January 24, 2017
    Publication date: May 18, 2017
    Inventors: Mark X. Sliwkowski, Scott Holden, Stuart Lutzker, Jay Tibbitts, Nelson L. Jumbe
  • Publication number: 20170095570
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Application
    Filed: September 30, 2016
    Publication date: April 6, 2017
    Applicant: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • Patent number: 9518118
    Abstract: The invention provides anti-HER2 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: December 13, 2016
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Jagath Reddy Junutula, Gail Lewis Phillips, Thomas Harden Pillow, Mark X. Sliwkowski